Indonesia clamps down on drug licences after 150 children die
Country’s food and drug agency revokes licences of syrup-type drug production of two local firms as it probes the deaths of more than 150 children from acute kidney injury
31 October 2022 - 13:34
UPDATED 31 October 2022 - 15:34
byStanley Widianto and Ananda Teresia
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Jakarta — Indonesia’s food and drug agency (BPOM) said on Monday that it had revoked licences of syrup-type drug production of two local firms for violating manufacturing rules, as it probes the deaths of more than 150 children due to acute kidney injury (AKI).
The decision comes after Indonesia temporarily banned sales of some syrup-based medications and identified the presence in some products of ethylene glycol and diethylene glycol as possible factors in the AKI deaths, most of which were of children under five.
The two are used in antifreeze and brake fluids and other industrial applications but also as a cheaper alternative in some pharmaceutical products to glycerine, a solvent or thickening agent in many cough syrups. They can be toxic and lead to acute kidney injury.
BPOM chief Penny K Lukito told reporters “oral liquid” manufacturing licences of the two companies, PT Yarindo Farmatama and PT Universal Pharmaceutical Industries, have been revoked, adding BPOM is pursuing criminal action against the companies.
The two firms produced drugs with substandard raw materials, failed to report a change in ingredients and used some materials in excess of guidelines, Penny said.
PT Yarindo Farmatama did not immediately respond to Reuters’ requests for comment. A lawyer with PT Universal Pharmaceutical Industries declined to comment, citing the ongoing investigation.
Indonesia has seen a surge in AKI cases among children since August, which its health minister said was most likely due to changes in the raw ingredients used in cough and fever syrups.
Indonesia imports its raw ingredients for medicine mostly from China and India, according to the health ministry.
Authorities said solvents used in the syrups from the two companies contained impurities.
BPOM said on Monday one of these solvents, propylene glycol, was made by Dow Chemical Thailand. The company did not immediately respond to a request for comment.
BPOM said it would look into distributors of the two drug makers to see if they supplied materials to other pharmaceutical firms.
Indonesia has been investigating AKI cases in consultation with the World Health Organization after a similar incident in Gambia earlier this year, which has seen at least 70 deaths related to syrup medications made by India’s Maiden Pharmaceuticals. Reuters
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Indonesia clamps down on drug licences after 150 children die
Country’s food and drug agency revokes licences of syrup-type drug production of two local firms as it probes the deaths of more than 150 children from acute kidney injury
Jakarta — Indonesia’s food and drug agency (BPOM) said on Monday that it had revoked licences of syrup-type drug production of two local firms for violating manufacturing rules, as it probes the deaths of more than 150 children due to acute kidney injury (AKI).
The decision comes after Indonesia temporarily banned sales of some syrup-based medications and identified the presence in some products of ethylene glycol and diethylene glycol as possible factors in the AKI deaths, most of which were of children under five.
The two are used in antifreeze and brake fluids and other industrial applications but also as a cheaper alternative in some pharmaceutical products to glycerine, a solvent or thickening agent in many cough syrups. They can be toxic and lead to acute kidney injury.
BPOM chief Penny K Lukito told reporters “oral liquid” manufacturing licences of the two companies, PT Yarindo Farmatama and PT Universal Pharmaceutical Industries, have been revoked, adding BPOM is pursuing criminal action against the companies.
The two firms produced drugs with substandard raw materials, failed to report a change in ingredients and used some materials in excess of guidelines, Penny said.
PT Yarindo Farmatama did not immediately respond to Reuters’ requests for comment. A lawyer with PT Universal Pharmaceutical Industries declined to comment, citing the ongoing investigation.
Indonesia has seen a surge in AKI cases among children since August, which its health minister said was most likely due to changes in the raw ingredients used in cough and fever syrups.
Indonesia imports its raw ingredients for medicine mostly from China and India, according to the health ministry.
Authorities said solvents used in the syrups from the two companies contained impurities.
BPOM said on Monday one of these solvents, propylene glycol, was made by Dow Chemical Thailand. The company did not immediately respond to a request for comment.
BPOM said it would look into distributors of the two drug makers to see if they supplied materials to other pharmaceutical firms.
Indonesia has been investigating AKI cases in consultation with the World Health Organization after a similar incident in Gambia earlier this year, which has seen at least 70 deaths related to syrup medications made by India’s Maiden Pharmaceuticals.
Reuters
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.